Loading...
OTCM
ENDV
Market cap31kUSD
Jul 08, Last price  
0.00USD
1D
0.00%
1Q
9,900.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

Endonovo Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:ENDV chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
171.66%
Rev. gr., 5y
-49.64%
Revenues
0k
-100.00%
60,00060,58547,76730,58122,89624,1924,2650083,263310,164165,79673,105135,355140,24210,0430
Net income
-2m
L-22.21%
-330,000-69,400-94,088-1,914,551-2,892,794-959,494-5,079,101-5,315,672-10,810,160-6,435,839-17,314,504-395,584-3,104,894-18,474,8356,924,594-2,797,297-2,176,130
CFO
-43k
L
-80,0008,502-50,354-284,891-257,416-909,296-1,019,334-2,462,334-2,989,770-2,878,834-2,541,007-741,590-986,584-678,838121,870100,487-42,991

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.
IPO date
Mar 09, 2012
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT